ABVC BioPharma, a clinical-stage biopharmaceutical company, said today that the Central Institutional Review Board has approved the company’s main product candidate, ABV-1505, for Phase II research in the treatment of ADHD. ABVC stock soars 201% today to the price of $7.75. Around 100 individuals will participate in Part 2 of the research in Taiwan. It’s a placebo-controlled, double-blind trial. The US Food and Drug Administration gave the business permission to undertake the first part of Phase 2 earlier this year.
The active component of ABV-1505, PDC-1421, was shown to be safe and well-tolerated in six adult patients with attention deficit hyperactivity disorder in Part 1 of the research. The proportion of improvement in the ADHD-RS-IV score for the high- and low-dose groups was 83% for the main endpoint. The research protocol for the company’s Phase II clinical trial for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) has been approved by the Taiwan Central IRB. In 2022 and 2023, the research will be undertaken in the United States and Taiwan. ABVC BioPharma is focused on performing proof-of-concept studies for its medication candidates and Vitargus®, a wearable medical device, which has a pipeline of six drug candidates and one medical device under development.